HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 333-275062 Commission file number IMPACT BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of (IRS Employer incorporation- or Organization) Identificatio ...

Company Overview - Universal Ibogaine Inc. (UI) is a life sciences company focused on researching and delivering medicalized ibogaine-centered addiction care [1][3] - The company aims to transform addiction treatment through a planned Canadian clinical trial targeting opioid use disorder and intends to expand its treatment protocol globally via future licensing agreements [3] Leadership Changes - Greg Leavens has resigned from his position as Chief Financial Officer and Corporate Secretary to pursue other opportunities, but will assist the company in a consulting capacity during the transition [1][2] Treatment Protocols - UI is developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre, located near Winnipeg, Manitoba, which will be paired with the planned ibogaine detox protocol [3]

Company Overview - Universal Ibogaine Inc. is a life sciences company focused on researching and delivering medicalized ibogaine-centered addiction care [4] - The company aims to transform addiction treatment through a planned Canadian clinical trial targeting opioid use disorder and intends to utilize this treatment protocol globally via future licensing agreements [4] Recent Developments - Ken Cranwill has resigned from the Board of Directors to focus on other business ventures, with the company expressing gratitude for his service over the past year [1] - The company has received approval from the TSX Venture Exchange to settle $106,200 in consulting fees owed to CEO Nick Karos by issuing 4,248,000 common shares at a price of $0.025 per share [2] - Following the share issuance, Universal Ibogaine will have a total of 312,858,516 common shares outstanding [2] Future Plans - The company is concurrently developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, which, when combined with the ibogaine detox protocol, aims to revolutionize addiction treatment and improve the lives of affected individuals and families [4]

A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other Jurisdiction of (IRS Employer incorporation- or Organization) Identification No.) Nevada 85-3926944 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 333-275062 Commission file number IMPACT BIOMEDICAL, INC. (Exact name of registrant as ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-32146 IMPACT BIOMEDICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) discovers, c ...

HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical’s focused roll-up strategy, expanding its portfolio with cutting-edge solutions that ...

Core Insights - Impact BioMedical Inc. has acquired Celios®, an air purification technology company, in an all-equity transaction valued at approximately $1.15 million, aligning with its roll-up strategy to enhance its portfolio and generate immediate revenue [1][3] - Celios® offers advanced air purification capabilities with patents ensuring exclusivity through 2043, providing "virtually clean room" air quality through innovative filter technology [2][4] - The acquisition is a significant milestone for Impact BioMedical, reinforcing its commitment to health and wellness solutions while maintaining a strong cash position to support growth [3] Company Overview - Impact BioMedical Inc. focuses on discovering, developing, and patenting unique technologies in biopharmaceuticals and consumer healthcare, collaborating with external partners for research and development [5] - Celios® is dedicated to improving indoor air quality through patented filtration solutions that are efficient and portable, meeting high standards of cleanliness and safety [4]